Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 7/20 | 0.66 |
| ▸ | CDK2 | P24941 | 4/20 | 0.61 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927607 | 0.94 | KIFC1 (0.57) | KIFC1CDK2GPR34MMEITGB1 | |
| SCHEMBL5927190 | 0.88 | KIFC1 (0.61) | KIFC1CDK2GPR34MMEITGB1 | |
| SCHEMBL5927777 | 0.86 | KIFC1 (0.71) | KIFC1CDK2GPR34MMEITGB1 | |
| SCHEMBL5926838 | 0.82 | CTSA (0.59) | KIFC1MMECTSA | |
| SCHEMBL6098431 | 0.82 | KIFC1 (0.69) | KIFC1CDK2GPR34MMEITGB1 | |
| SCHEMBL5926297 | 0.81 | CTSA (0.54) | GPR34MMEITGB1ITGA4ITGB7 | |
| SCHEMBL5926987 | 0.81 | PTPN1 (0.55) | CDK2GPR34MMEITGB1ITGB3 | |
| SCHEMBL6097847 | 0.81 | KIFC1 (0.68) | KIFC1CDK2GPR34MMEITGB1 | |
| SCHEMBL5926237 | 0.81 | KIFC1 (0.53) | KIFC1CDK2GPR34MMEGPR132 | |
| SCHEMBL8338544 | 0.81 | KIFC1 (0.53) | KIFC1CDK2GPR34MMEITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | KIFC1 4489/4885CDK2 1006/4885GPR34 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.